Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evizon
- Development stage
- Discontinued
- Lead developer
- Genaera
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Evizon (squalamine lactate)** is a small molecule aminosterol developed by Genaera Corporation for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of vision loss. It acts by inhibiting vascular endothelial growth factor (VEGF) and other angiogenic factors, disrupting pathological neovascularization in the eye. Administered intravenously, Phase II trials showed dose-dependent stabilization or improvement in bilateral visual acuity, particularly in patients with advanced disease in fellow eyes; however, Phase III development was terminated in 2007 due to insufficient vision improvement compared to emerging standards like Lucentis (ranibizumab), slow enrollment, and lack of partnering interest.
- Brand names
- Evizon
02
Targets
αVβ3 (Integrin αVβ3)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Evizon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evizon.